Every peptide and blend on this site, with the routes and routines the published and community sources mention — each row linked to where it came from, so you can check it yourself. We report what the sources say; we don't invent numbers, and where the research is silent, we say so.
18 of 26 compounds have sourced dosing notes; the rest are listed honestly as not-yet-documented. Companion to the 2026 Reference Guide (the PDF links here).
IV and oral administration (specific dose not specified in text)
Intravenous, Oral
5 mg BPC-157 + 5 mL BAC water
Subcutaneous, Intramuscular, Intra-articular
Daily
Subcutaneous, Oral
Single administration demonstrating effects lasting up to 24 hours
Unspecified
Self-administered injectable medication
Subcutaneous injection
CJC-1295: 50-100 mcg; Ipamorelin: 100-200 mcg
Subcutaneous Injection
100 mcg CJC-1295 + 100-200 mcg Ipamorelin
Subcutaneous
25 nmol/kg
Intravenous
Intravenous administration on 5 consecutive days followed by 5 injections every 48-72 h
Intravenous
100–500 mcg once daily SC before bedtime
SC
1 µg/mouse
Subcutaneous injection
5 mg once daily SC for 20 days, then 4–6 months off-cycle
SC
In Vitro / Cell Culture
Topical application
Topical
Intranasal
Topical
Parenteral (Injection)
100–250 mcg once daily SC (research: 100–300 mcg 2–3×/day)
SC
Contains GHK-Cu, BPC-157, TB-500, KPV
500 mcg each of TB-500, BPC-157 and KPV + 2.5 mg GHK-Cu once daily SC (range 250–750 mcg each)
SC
10^-12 M to 10^-3 M (Cosmetic)
Topical
Intraperitoneal injection (mice)
Injection
Intraperitoneal injection
Selank: 200–300 mcg; Semax: 200–400 mcg
Intranasal
7–14 mg
Oral
~400 mg
Oral
0.5 mg and 1.0 mg
Subcutaneous injection
0.25 mg once weekly, escalating to 0.5 mg, 1 mg, 1.7 mg, and maintenance 2.4 mg
Subcutaneous injection
10 μg/kg
Systemic (injection, murine model)
10 μg/kg, administered 120 minutes before oral glucose challenge
Systemic (injection, murine model)
Once daily
Oral
Varies; reports of doses beyond FDA-approved label limits
Injectable
Start low, increase every 4 weeks up to 25 mg
Oral
Maximum dose of 2.4 mg
Injection
Once-weekly injection
Subcutaneous (abdomen, thigh, or upper arm)
3 mg once daily for 30 days, then increase to 7 mg once daily. If blood glucose levels are still too high after another 30 days, provider may increase dose to 14 mg once daily.
Oral
0.25 mg once weekly for the first 4 weeks, then increase to 0.5 mg once weekly. If blood glucose levels are still too high, dose may continue to increase every 4 weeks until reaching the effective amount (up to 2 mg once weekly).
Subcutaneous injection
Up to 120 mL water, fast for 30 min post-dose
Oral
Once-weekly
Subcutaneous
25mg
Oral
3mg to 14mg
Oral
2.4 mg weekly
Injection
25 mg once daily
Oral
Days 31 through 60
Oral
Days 61 through 90
Oral
Initiate 25 mg maintenance dosage
Oral
Filled prescription within 180 days of bariatric surgery
Unknown
0.5-100 mg (including ranges of 0.5-50 mg, 0.5-25mg, 1-25 mg, 5-50 mg, 0.5-10 mg, 0.5-5 mg)
Oral
25mg daily
oral
Subcutaneous injection
0.1-50 mg
Oral
Up to 2.4 mg weekly
Subcutaneous Injection
Up to 2 mg weekly
Subcutaneous Injection
Up to 2.4 mg once weekly
Subcutaneous Injection
Once weekly
Subcutaneous Injection
7.2 mg
Subcutaneous injection
25 mg
Oral
0.5 mg, 1 mg, or 2 mg
Subcutaneous injection
4 mg or 9 mg
Oral
25 mg and 50 mg vs 14 mg
Oral
0.25 mg weekly (Weeks 1-4), 0.5 mg weekly (Weeks 5-8), 1.0 mg weekly (Week 9+)
Subcutaneous
0.25 mg (Weeks 1-4) -> 0.5 mg (Weeks 5-8) -> 1.0 mg (Weeks 9-12) -> 1.7 mg (Weeks 13-16) -> 2.4 mg (Week 17+)
Subcutaneous Injection
1.5 mg (4 weeks) -> 4 mg (4 weeks) -> 9 mg (4 weeks) -> 25 mg (maintenance)
Oral
Not specified in sources
Injection
200-900 mcg/day
Intranasal
3,000-9,000 mcg/day
Intranasal
200-600 mcg daily
Intranasal
2 to 3 drops per nostril, 2 to 3 times daily (200 to 900 mcg/day)
Intranasal
3,000 to 9,000 mcg daily
Intranasal
200–500 mcg once daily SC (intranasal: 600–1500 mcg/day)
SC
Not specified (implied injection/administration)
Tesamorelin 1–1.4 mg + Ipamorelin 100–200 mcg
Subcutaneous
1.6 mg (900 µg/m²) subcutaneously twice a week for 6 to 12 months
Subcutaneous
Up to 15 mg
Subcutaneous injection
Once weekly subcutaneous injection
Subcutaneous
Once weekly injection under the skin
Subcutaneous
Injected once weekly
Subcutaneous injection
36-week trial duration
Unspecified
Once weekly injection
Subcutaneous
Once-weekly subcutaneous dosing
Subcutaneous
10 mg or 15 mg
Subcutaneous injection
These compounds are in our library, but the sources we've collected don't include dosing details. When a sourced note exists, it appears above — never a guess.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.